228 related articles for article (PubMed ID: 7695281)
21. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
Knapp CC; Sierra-Madero J; Washington JA
Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
[TBL] [Abstract][Full Text] [Related]
22. In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.
Edelstein PH; Edelstein MA
Antimicrob Agents Chemother; 1994 Feb; 38(2):200-4. PubMed ID: 8192443
[TBL] [Abstract][Full Text] [Related]
23. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.
Ling TK; Ying CM; Lee CC; Liu ZK
Med Princ Pract; 2005; 14(5):338-41. PubMed ID: 16103700
[TBL] [Abstract][Full Text] [Related]
24. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Bonomo RA; Rudin SA; Shlaes DM
FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of YTR 830.
Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
[TBL] [Abstract][Full Text] [Related]
26. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
Gill CJ; Ponticas S; Shungu DL; Guerriero S
Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis.
Tweardy DJ; Jacobs MR; Speck WT
J Antimicrob Chemother; 1983 Aug; 12(2):133-9. PubMed ID: 6555189
[TBL] [Abstract][Full Text] [Related]
28. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
[TBL] [Abstract][Full Text] [Related]
29. In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Verhaegen J; Verbist L
J Antimicrob Chemother; 1998 Mar; 41(3):381-5. PubMed ID: 9578165
[TBL] [Abstract][Full Text] [Related]
30. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
Akova M; Yang Y; Livermore DM
J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
[TBL] [Abstract][Full Text] [Related]
31. Susceptibilities of 23 Desulfovibrio isolates from humans.
Nakao K; Tanaka K; Ichiishi S; Mikamo H; Shibata T; Watanabe K
Antimicrob Agents Chemother; 2009 Dec; 53(12):5308-11. PubMed ID: 19786606
[TBL] [Abstract][Full Text] [Related]
32. Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children.
Citron DM; Goldstein EJ; Kenner MA; Burnham LB; Inderlied CB
Clin Infect Dis; 1995 Jun; 20 Suppl 2():S356-60. PubMed ID: 7548597
[TBL] [Abstract][Full Text] [Related]
33. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.
Jones RN; Pfaller MA; Fuchs PC; Aldridge K; Allen SD; Gerlach EH
Diagn Microbiol Infect Dis; 1989; 12(6):489-94. PubMed ID: 2560421
[TBL] [Abstract][Full Text] [Related]
34. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
Shlaes DM; Baughman R; Boylen CT; Chan JC; Charan NB; Cormier YC; Erickson A; Grossman R; Kirmani N; Suh B
J Antimicrob Chemother; 1994 Oct; 34(4):565-77. PubMed ID: 7868408
[TBL] [Abstract][Full Text] [Related]
35. Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes.
Aldridge KE; Morice N; Schiro DD
Diagn Microbiol Infect Dis; 1994 Aug; 19(4):227-34. PubMed ID: 7851086
[TBL] [Abstract][Full Text] [Related]
36. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J
Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
[TBL] [Abstract][Full Text] [Related]
37. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
Livermore DM; Yuan M
J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
[TBL] [Abstract][Full Text] [Related]
38. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci.
Pankuch GA; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1995 Jun; 35(6):883-8. PubMed ID: 7559200
[TBL] [Abstract][Full Text] [Related]
39. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Zhao C; Xie W; Zhang W; Ye Z; Wu H
Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
[TBL] [Abstract][Full Text] [Related]
40. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
